0.03Open0.03Pre Close0 Volume356 Open Interest2.50Strike Price0.00Turnover134.20%IV40.05%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0466Delta0.0713Gamma137.33Leverage Ratio-0.0029Theta-0.0001Rho-6.40Eff Leverage0.0010Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet